Open AccessTAVI: New trials and registries offer further welcome evidence – U.S. CoreValve, CHOICE, and GARY
Author(s) -
Michele Pighi,
Roberta Serdoz,
İsmail Doğu Kılıç,
Sara Abou Sherif,
Alistair C Lindsay,
Carlo Di Mario
Publication year - 2014
Publication title -
global cardiology science and practice
Language(s) - English
Resource type - Journals
ISSN - 2305-7823
DOI - 10.5339/gcsp.2014.12
Subject(s) - medicine , stenosis , cardiology , aortic valve replacement , clinical trial , aortic valve stenosis , surgery
The introduction of transcatheter aortic valve implantation (TAVI) has resulted in a paradigm shift in the treatment of patients with severe aortic stenosis. Data from the recent U.S CoreValve Trial suggest, for the first time, that TAVI is associated with a significantly higher rate of survival at one year compared to surgical aortic valve replacement (SAVR) in the treatment of high-risk patients affected by severe aortic stenosis. The present review discusses this study and the current evidence about TAVI, for the treatment of severe aortic stenosis, from major trials and real world registries.